A line in shifting sand: Can we define and target TP53 mutated MDS?

Abstract excerpt

Mutations in the tumor suppressor protein, TP53, lead to dismal outcomes in myeloid malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Recent pathological reclassifications have integrated TP53 mutated MDS and AML under a unified category of TP53 mutated myeloid neoplasms, which allows for more flexibility in treatment approaches. Therapeutic strategies have predominantly...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to TP53 gene
• Share to Leukemia, Myeloid, Acute
• Share to Mutation